Resumen de: WO2023284035A1

A neurodegenerative disease marker and an application thereof. The neurodegenerative disease marker comprises a cystatin C coding gene NM_009976.4. It is found for the first time that the expression of cystatin C coding gene in Alzheimer disease brain tissue (cortex, hippocampus, and synapse) is down-regulated, but the level of cystatin C protein in the peripheral serum of Alzheimer disease is increased, and therefore, early diagnosis of Alzheimer disease can be performed by measuring the indicators.

Resumen de: US2023017557A1

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues, using blood samples, to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Resumen de: US2023021187A1

A substance that can be a substitute for amylospheroids (ASPD) and a method for analyzing ASPD are provided. Viewed from one aspect, the present disclosure relates to a substance in which amyloid-β protein (Aβ) is cross-linked with a cross-linking agent that has a spacer arm length of between 4 Å and 50 Å inclusive or a cross-linking agent that has, as a spacer arm, not less than 1 and not more than 13 groups that are an oxyethylene group(s) (—CH2CH2O—) and/or an oxypropylene group(s) (—CH2CH2CH3O—). Viewed from another aspect, the present disclosure relates to a method for analyzing ASPD using the substance as a reference material.

Resumen de: WO2023285462A1

Disclosed are N-acylphosphatidylethanolamine (NAPE) molecules as biomarkers for Alzheimer's disease (AD), the use thereof in a method for the diagnosis or prognosis of AD, and a kit for implementation of the method.

Resumen de: AU2022252753A1

The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody.

Resumen de: WO2021181364A1

The present disclosure relates to the use of PGC-1α expression to identify a subject that is conducive to treatment with a miR-485 inhibitor. In some aspects, the subject suffers from a disease or disorder associated with reduced PGC-1α expression. In some aspects, the PGC-1α expression is measured in the serum of the subject.

Resumen de: WO2021181365A1

The present disclosure relates to the use of SIRT1 expression to identify a subject that is conducive to treatment with a miR-485 inhibitor. In some aspects, the subject suffers from a disease or disorder associated with reduced SIRT1 expression. In some aspects, the SIRT1 expression is measured in the serum of the subject.

Resumen de: WO2023283021A1

Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.

Resumen de: WO2023283650A1

Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

Resumen de: EP3309550A1

The present invention provides a method for the detection of Apolipoprotein E isotype 4 (ApoE4) or fragments thereof in a blood sample of a subject, whereby said method comprises the steps of contacting said sample with a solid phase, contacting said sample with at least one binder binding specifically to ApoE4 or a fragment thereof, thereby forming an ApoE4binder-complex, and detecting the ApoE4-binder-complex.

Resumen de: US2023003721A1

Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from Aβ(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice. The MnMs were demonstrated to protect the mitochondrial population in neurons in an in vivo model of Alzheimer's Disease. Also described is a method for treating a patient suffering from a disorder characterized by dysfunction of neuronal mitostasis, comprising administering to the patient a therapeutically effective amount of a compound (MnM), or a pharmaceutically acceptable salt thereof.

Resumen de: WO2023277459A1

The present invention relates to a screening method of a therapeutic agent for brain diseases. Specifically, the screening method according to the present invention can be useful for screening a therapeutic agent for brain diseases. The screening method is based on the fact that Rg3, which is known to have a therapeutic effect for Alzheimer's disease, promotes NF-κB signaling mechanisms while promoting M2 polarization and suppressing M1 polarization, suppresses Aβ accumulation by increasing SRA protein expression, and suppresses water-soluble APPα processing in neural cells through water-soluble APPα generation and the suppression of Aβ42 generation by increasing ADAM10 protein expression in microglia or neuroblastoma.

Resumen de: WO2023272576A1

Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.

Resumen de: WO2021219917A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

Resumen de: US2023003744A1

Embodiments of the disclosure are directed to biomarkers, or a panel of biomarkers, that determine progression of Alzheimer's disease, and methods of use thereof.

Resumen de: WO2021228125A1

The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

Resumen de: WO2022270112A1

[Abstract] Corosolic acid improves insulin resistance and recovers an insulin function that is deteriorated with age. As a result, the insulin sensitivity in an aged person is improved and the metabolism in all cells gets active. [Problem] The problem to be solved by the present invention is to alleviate and ameliorate an adult disease, a lifestyle-related disease, dementia and the like associated with insulin resistance and achieve a long healthy life-span by corosolic acid and an analogue thereof. There is a finding about a composition which recovers a function inherent to insulin again against the slowing down of an insulin reaction or insulin resistance that is believed as a main cause of an adult disease, a lifestyle-related disease, dementia or the like and is consequently useful for the delay of progression or prevention of an adult disease, a lifestyle-related disease, dementia/Alzheimer's disease or the like, and an idea about a specific method is proposed.

Resumen de: US2022411489A1

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

Resumen de: US2022412949A1

A composition having one or more nanoneedles is provided, where each nanoneedle has a silver tip and one or more of the silver tips comprise an AgCl layer. In one approach, one or more of the silver tips further include a layer of thiol-polyethylene glycol. A method of resistive pulse detection involving a protein pore is also provided. The method involves reconstituting one or more protein pores in a lipid membrane formed on the tip of a nanoneedle, then applying a potential across the membrane and detecting resistive pulses.

Resumen de: WO2021165465A1

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.

Resumen de: US2018265575A1

Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

Resumen de: NZ748983A

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer s disease and other tauopathies.

Resumen de: US2022404376A1

The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.

Resumen de: US2022406435A1

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

Resumen de: US2022402979A1

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure further provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment.